Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Galenica AB

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against the company in the U.S. that alleged its discontinued drug Zantac caused cancer....

Automated dispensing

Are you interested in automated dispensing of liquids?

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Ny ledamot i Läkemedelsverkets styrelse – ”Ett uppdrag jag tar på stort allvar”

Regeringen har utsett Sveriges Farmaceuters tidigare ordförande Thony Björk till ledamot i Läkemedelsverkets styrelse.

EXCL Gantry Kit Improve Automated Lab Applications

We’re excited to introduce a new product that improves precision and throughput in life science applications. The EXCL multi-axis gantry kit lowers engineering ...

Wusson Accelerator AB

Gothenburg-based company acquired by Norwegian diagnostics group

Gentian Diagnostics acquires Gothenburg-based Getica.

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Recipharm divests five Swedish plants

Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity company Blue Wolf Capital Partners....

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

WuXi AppTec, UK Ltd

Revealing the secrets of a part

CT inspection in automation technology at Festo.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

Kvinnan bakom Novo Nordisks fetmasuccé: ”Slutade aldrig tro på GLP-1”

Det tog flera år av misslyckanden inom GLP-1 innan Lotte Bjerre Knudsen och hennes kollegor hittade rätt – men då var det en riktig fullträff. ”Vi investerade i...

Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"

Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...

Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide

AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...

Danish obesity success causes recruitment problems in southern Sweden

The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."